Development of lipidoid-siRNA formulations for systemic delivery to the liver.

RNA interference therapeutics afford the potential to silence target gene expression specifically, thereby blocking production of disease-causing proteins. The development of safe and effective systemic small interfering RNA (siRNA) delivery systems is of central importance to the therapeutic application of siRNA. Lipid and lipid-like materials are currently the most well-studied siRNA delivery systems for liver delivery, having been utilized in several animal models, including nonhuman primates. Here, we describe the development of a multicomponent, systemic siRNA delivery system, based on the novel lipid-like material 98N(12)-5(1). We show that in vivo delivery efficacy is affected by many parameters, including the formulation composition, nature of particle PEGylation, degree of drug loading, and biophysical parameters such as particle size. In particular, small changes in the anchor chain length of poly(ethylene glycol) (PEG) lipids can result in significant effects on in vivo efficacy. The lead formulation developed is liver targeted (>90% injected dose distributes to liver) and can induce fully reversible, long-duration gene silencing without loss of activity following repeat administration.

[1]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[2]  P. Cullis,et al.  Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. , 2001, Biochimica et biophysica acta.

[3]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Bally,et al.  Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity , 1999, Nature Biotechnology.

[5]  L. Palmer,et al.  Lipid-based systems for the intracellular delivery of genetic drugs. , 1999, Molecular membrane biology.

[6]  M. Bally,et al.  The liposomal formulation of doxorubicin. , 2005, Methods in enzymology.

[7]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[8]  M. Bally,et al.  Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. , 1998, Biochimica et biophysica acta.

[9]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[10]  Darren H. Wakefield,et al.  Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.

[11]  Phillip A. Sharp,et al.  The RNAi revolution , 2004, Nature.

[12]  J. Heyes,et al.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[13]  S. Lowe,et al.  Tissue-specific and reversible RNA interference in transgenic mice , 2007, Nature Genetics.

[14]  L. Medina-Kauwe,et al.  Intracellular trafficking of nonviral vectors , 2005, Gene Therapy.

[15]  L. Palmer,et al.  Stabilized plasmid-lipid particles: construction and characterization , 1999, Gene Therapy.

[16]  F. Szoka,et al.  Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes* , 2003, Journal of Biological Chemistry.

[17]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[18]  E. Wisse,et al.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.

[19]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[20]  Feng Liu,et al.  Development of non-viral vectors for systemic gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Tariq M Rana,et al.  Design and creation of new nanomaterials for therapeutic RNAi. , 2007, ACS chemical biology.

[22]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[23]  N. Boyce.  Trial halted after gene shows up in semen , 2001, Nature.

[24]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[25]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[26]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[27]  A. D. Fougerolles.  Delivery vehicles for small interfering RNA in vivo. , 2008 .

[28]  F. Szoka,et al.  Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.

[29]  R. Wattiaux,et al.  Endosomes, lysosomes: their implication in gene transfer. , 2000, Advanced drug delivery reviews.

[30]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[31]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[32]  N. K. Jain,et al.  Pharmaceutical and biomedical potential of surface engineered dendrimers. , 2007, Critical reviews in therapeutic drug carrier systems.

[33]  E. Wagner,et al.  Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[34]  M. Hope,et al.  Membrane perturbation and the mechanism of lipid-mediated transfer of DNA into cells. , 2000, Biochimica et biophysica acta.

[35]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[36]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[37]  Shubiao Zhang,et al.  Cationic lipids and polymers mediated vectors for delivery of siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[39]  G. Cheon,et al.  Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.